Gastrointestinal tract malignancies and positron emission tomography: An overview

Seminars in Nuclear Medicine

Volumn 36, Issue 2, 2006, Pages 169-181

  Esteves, Fabio P ^a   Schuster, David M ^a   Halkar, Raghuveer K ^a  

^a EMORY UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; IMATINIB; OCTREOTIDE; YTTRIUM 90;

ADJUVANT THERAPY; ANATOMY; ARTIFICIAL EMBOLISM; BILE DUCT CARCINOMA; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; COLORECTAL CANCER; COMPARATIVE STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIGESTIVE SYSTEM CANCER; ESOPHAGUS CANCER; GALLBLADDER CANCER; GASTROINTESTINAL TUMOR; HISTOPATHOLOGY; HUMAN; IMAGING; MONITORING; OUTCOMES RESEARCH; PANCREAS CANCER; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PREOPERATIVE EVALUATION; PROGNOSIS; RADIOFREQUENCY ABLATION; REVIEW; SENSITIVITY ANALYSIS; STOMACH CARCINOMA; TUMOR RECURRENCE;

COLORECTAL NEOPLASMS; ESOPHAGEAL NEOPLASMS; FLUORODEOXYGLUCOSE F18; HUMANS; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; STOMACH NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33644628349     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2005.12.002     Document Type: Review

References (100)

1. D.C. Mauchley, D.C. Lynge, L.A. Langdale Clinical utility and cost-effectiveness of routine preoperative computed tomography scanning in patients with colon cancer Am J Surg 189 2005 512 517 discussion 517
2. A. Filippone, R. Ambrosini, M. Fuschi Preoperative T and N staging of colorectal cancer Accuracy of contrast-enhanced multi-detector row CT colonography-initial experience Radiology 231 2004 83 90
3. S. Friedland, R. Soetikno, M. Carlisle 18-Fluorodeoxyglucose positron emission tomography has limited sensitivity for colonic adenoma and early stage colon cancer Gastrointest Endosc 61 2005 395 400
4. F. Gutman, J.L. Alberini, M. Wartski Incidental colonic focal lesions detected by FDG PET/CT AJR Am J Roentgenol 185 2005 495 500
5. E.M. Kamel, M. Thumshirn, K. Truninger Significance of incidental 18F-FDG accumulations in the gastrointestinal tract in PET/CT Correlation with endoscopic and histopathologic results J Nucl Med 45 2004 1804 1810
6. M.C. van Kouwen, F.M. Nagengast, J.B. Jansen 2-(18F)-fluoro-2-deoxy-D- glucose positron emission tomography detects clinical relevant adenomas of the colon a prospective study J Clin Oncol 23 2005 3713 3717
7. H. Abdel-Nabi, R.J. Doerr, D.M. Lamonica Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET Correlation with histopathologic and CT findings Radiology 206 1998 755 760
8. M. Mukai, S. Sadahiro, S. Yasuda Preoperative evaluation by whole-body 18F-fluorodeoxyglucose positron emission tomography in patients with primary colorectal cancer Oncol Rep 7 2000 85 87
9. I. Kantorova, L. Lipska, O. Belohlavek Routine (18)F-FDG PET preoperative staging of colorectal cancer Comparison with conventional staging and its impact on treatment decision making J Nucl Med 44 2003 1784 1788
10. D.A. August, R.T. Ottow, P.H. Sugarbaker Clinical perspective of human colorectal cancer metastasis Cancer Metastasis Rev 3 1984 303 324
11. S. Bipat, M.S. van Leeuwen, E.F. Comans Colorectal liver metastases CT, MR imaging, and PET for diagnosis-meta-analysis Radiology 237 2005 123 131
12. K. Kinkel, Y. Lu, M. Both Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET) A meta-analysis Radiology 224 2002 748 756
13. L. Staib, H. Schirrmeister, S.N. Reske Is (18)F-fluorodeoxyglucose positron emission tomography in recurrent colorectal cancer a contribution to surgical decision making? Am J Surg 180 2000 1 5
14. P.E. Valk, E. Abella-Columna, M.K. Haseman Whole-body PET imaging with [18F]fluorodeoxyglucose in management of recurrent colorectal cancer Arch Surg 134 1999 503 511 discussion 511-503
15. M.H. Whiteford, H.M. Whiteford, L.F. Yee Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum Dis Colon Rectum 43 2000 759 767 discussion 767-770
16. D.T. Lai, M. Fulham, M.S. Stephen The role of whole-body positron emission tomography with [18F]fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver Arch Surg 131 1996 703 707
17. J.V. Vitola, D. Delbeke, M.P. Sandler Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver Am J Surg 171 1996 21 26
18. D. Delbeke, J.V. Vitola, M.P. Sandler Staging recurrent metastatic colorectal carcinoma with PET J Nucl Med 38 1997 1196 1201
19. R. Hustinx, P. Paulus, N. Jacquet Clinical evaluation of whole-body 18F-fluorodeoxyglucose positron emission tomography in the detection of liver metastases Ann Oncol 9 1998 397 401
20. V. Kalff, R.J. Hicks, R.E. Ware The clinical impact of (18)F-FDG PET in patients with suspected or confirmed recurrence of colorectal cancer A prospective study J Nucl Med 43 2002 492 499
21. R.H. Huebner, K.C. Park, J.E. Shepherd A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer J Nucl Med 41 2000 1177 1189
22. C.G. Moertel, T.R. Fleming, J.S. Macdonald An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer JAMA 270 1993 943 947
23. R.H. Fletcher Carcinoembryonic antigen Ann Intern Med 104 1986 66 73
24. J.L. McCall, R.B. Black, C.A. Rich The value of serum carcinoembryonic antigen in predicting recurrent disease following curative resection of colorectal cancer Dis Colon Rectum 37 1994 875 881
25. B. Engaras Individual cutoff levels of carcinoembryonic antigen and CA 242 indicate recurrence of colorectal cancer with high sensitivity Dis Colon Rectum 46 2003 313 321
26. F.L. Flanagan, F. Dehdashti, O.A. Ogunbiyi Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer Ann Surg 227 1998 319 323
27. T.J. Ruers, B.S. Langenhoff, N. Neeleman Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases a prospective study J Clin Oncol 20 2002 388 395
28. A. Venook Critical evaluation of current treatments in metastatic colorectal cancer Oncologist 10 2005 250 261
29. M. Findlay, H. Young, D. Cunningham Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases Correlation with tumor response to fluorouracil J Clin Oncol 14 1996 700 708
30. H. Kahn, A. Alexander, J. Rakinic Preoperative staging of irradiated rectal cancers using digital rectal examination, computed tomography, endorectal ultrasound, and magnetic resonance imaging does not accurately predict T0, N0 pathology Dis Colon Rectum 40 1997 140 144
31. J.G. Guillem, H.G. Moore, T. Akhurst Sequential preoperative fluorodeoxyglucose-positron emission tomography assessment of response to preoperative chemoradiation A means for determining longterm outcomes of rectal cancer J Am Coll Surg 199 2004 1 7
32. H. Amthauer, T. Denecke, B. Rau Response prediction by FDG-PET after neoadjuvant radiochemotherapy and combined regional hyperthermia of rectal cancer Correlation with endorectal ultrasound and histopathology Eur J Nucl Med Mol Imaging 31 2004 811 819
33. D.W. Barker, R.J. Zagoria, K.A. Morton Evaluation of liver metastases after radiofrequency ablation utility of 18F-FDG PET and PET/CT AJR Am J Roentgenol 184 2005 1096 1102
34. L. Solbiati, T. Livraghi, S.N. Goldberg Percutaneous radio-frequency ablation of hepatic metastases from colorectal cancer long-term results in 117 patients Radiology 221 2001 159 166
35. P. Limanond, P. Zimmerman, S.S. Raman Interpretation of CT and MRI after radiofrequency ablation of hepatic malignancies AJR Am J Roentgenol 181 2003 1635 1640
36. S.N. Goldberg, G.S. Gazelle, P.R. Mueller Thermal ablation therapy for focal malignancy A unified approach to underlying principles, techniques, and diagnostic imaging guidance AJR Am J Roentgenol 174 2000 323 331
37. R. Lencioni, D. Cioni, C. Bartolozzi Percutaneous radiofrequency thermal ablation of liver malignancies Techniques, indications, imaging findings, and clinical results Abdom Imaging 26 2001 345 360
38. B.S. Langenhoff, W.J. Oyen, G.J. Jager Efficacy of fluorine-18- deoxyglucose positron emission tomography in detecting tumor recurrence after local ablative therapy for liver metastases a prospective study J Clin Oncol 20 2002 4453 4458
39. V. Donckier, J.L. Van Laethem, S. Goldman [F-18] fluorodeoxyglucose positron emission tomography as a tool for early recognition of incomplete tumor destruction after radiofrequency ablation for liver metastases J Surg Oncol 84 2003 215 223
40. G. Antoch, F.M. Vogt, P. Veit Assessment of liver tissue after radiofrequency ablation Findings with different imaging procedures J Nucl Med 46 2005 520 525
41. J.E. Dancey, F.A. Shepherd, K. Paul Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres J Nucl Med 41 2000 1673 1681
42. C.Y. Wong, R. Salem, S. Raman Evaluating 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18F]FDG PET A comparison with CT or MRI Eur J Nucl Med Mol Imaging 29 2002 815 820
43. C.Y. Wong, R. Salem, F. Qing Metabolic response after intraarterial 90Y-glass microsphere treatment for colorectal liver metastases Comparison of quantitative and visual analyses by 18F-FDG PET J Nucl Med 45 2004 1892 1897
44. M. Bienert, B. McCook, B.I. Carr 90Y microsphere treatment of unresectable liver metastases Changes in 18F-FDG uptake and tumour size on PET/CT Eur J Nucl Med Mol Imaging 32 2005 778 787
45. J. Brunetti, A. Caggiano, C. Vialotti Functional anatomic imaging in radiation therapy planning Cancer J 10 2004 214 220
46. S. Yasuda, S. Raja, K.F. Hubner Application of whole-body positron emission tomography in the imaging of esophageal cancer Report of a case Surg Today 25 1995 261 264
47. M. Sasaki, Y. Ichiya, Y. Kuwabara Fluorine-18-fluorodeoxyglucose positron emission tomography in technetium-99m-hydroxymethylenediphosphate negative bone tumors J Nucl Med 34 1993 288 290
48. T. Fukunaga, K. Enomoto, S. Okazumi [Analysis of glucose metabolism in patients with esophageal cancer by PET: Estimation of hexokinase activity in the tumor and usefulness for clinical assessment using 18F-fluorodeoxyglucose] Nippon Geka Gakkai Zasshi 95 1994 317 325
49. CMS Coverage Issues Manual Diagnostic Services. Available at: http://cms.hhs.gov/manuals/06_cim/ci50.asp#_50_36. Accessed March 1, 2004
50. T. Torizuka, K.R. Zasadny, R.L. Wahl Diabetes decreases FDG accumulation in primary lung cancer Clin Positron Imaging 2 1999 281 287
51. H.L. van Westreenen, D.C. Cobben, P.L. Jager Comparison of 18F-FLT PET and 18F-FDG PET in esophageal cancer J Nucl Med 46 2005 400 404
52. P.L. Jager, T.H. Que, W. Vaalburg Carbon-11 choline or FDG-PET for staging of oesophageal cancer? Eur J Nucl Med 28 2001 1845 1849
53. P. Flamen, A. Lerut, E. Van Cutsem Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma J Clin Oncol 18 2000 3202 3210
54. Y.C. Yoon, K.S. Lee, Y.M. Shim Metastasis to regional lymph nodes in patients with esophageal squamous cell carcinoma CT versus FDG PET for presurgical detection prospective study Radiology 227 2003 764 770
55. S.S. Gambhir, J. Czernin, J. Schwimmer A tabulated summary of the FDG PET literature J Nucl Med 42 2001 1S 93S
56. S.J. Skehan, A.L. Brown, M. Thompson Imaging features of primary and recurrent esophageal cancer at FDG PET Radiographics 20 2000 713 723
57. T. Fukunaga, S. Okazumi, Y. Koide Evaluation of esophageal cancers using fluorine-18-fluorodeoxyglucose PET J Nucl Med 39 1998 1002 1007
58. K. Kim, S.J. Park, B.T. Kim Evaluation of lymph node metastases in squamous cell carcinoma of the esophagus with positron emission tomography Ann Thorac Surg 71 2001 290 294
59. F.L. Flanagan, F. Dehdashti, B.A. Siegel Staging of esophageal cancer with 18F-fluorodeoxyglucose positron emission tomography AJR Am J Roentgenol 168 1997 417 424
60. M.I. Block, G.A. Patterson, R.S. Sundaresan Improvement in staging of esophageal cancer with the addition of positron emission tomography Ann Thorac Surg 64 1997 770 776 discussion 776-777
61. P.A. Heeren, P.L. Jager, F. Bongaerts Detection of distant metastases in esophageal cancer with (18)F-FDG PET J Nucl Med 45 2004 980 987
62. E.I. Sihvo, J.V. Rasanen, M.J. Knuuti Adenocarcinoma of the esophagus and the esophagogastric junction Positron emission tomography improves staging and prediction of survival in distant but not in locoregional disease J Gastrointest Surg 8 2004 988 996
63. P. Flamen, T. Lerut, K. Haustermans Position of positron emission tomography and other imaging diagnostic modalities in esophageal cancer Q J Nucl Med Mol Imaging 48 2004 96 108
64. A.N. Patel, P.O. Buenaventura Current staging of esophageal carcinoma Surg Clin North Am 85 2005 555 567
65. NCCN Clinical Practice Guidelines in Oncology. Esophageal Cancer. Version 1.2005. Available at: http://www.nccn.org/professionals/physician_gls/PDF/ esophageal.pdf. Accessed October 12, 2005
66. F. Dehdashti, B.A. Siegel Neoplasms of the esophagus and stomach Semin Nucl Med 34 2004 198 208
67. J.D. Luketich, P.R. Schauer, C.C. Meltzer Role of positron emission tomography in staging esophageal cancer Ann Thorac Surg 64 1997 765 769
68. J.D. Luketich, D.M. Friedman, T.L. Weigel Evaluation of distant metastases in esophageal cancer 100 consecutive positron emission tomography scans Ann Thorac Surg 68 1999 1133 1136 discussion 1136-1137
69. C.C. Meltzer, J.D. Luketich, D. Friedman Whole-body FDG positron emission tomographic imaging for staging esophageal cancer comparison with computed tomography Clin Nucl Med 25 2000 882 887
70. J.Y. Choi, K.H. Lee, Y.M. Shim Improved detection of individual nodal involvement in squamous cell carcinoma of the esophagus by FDG PET J Nucl Med 41 2000 808 815
71. R. Bar-Shalom, L. Guralnik, M. Tsalic The additional value of PET/CT over PET in FDG imaging of oesophageal cancer Eur J Nucl Med Mol Imaging 32 2005 918 924
72. T. Lerut, P. Flamen, N. Ectors Histopathologic validation of lymph node staging with FDG-PET scan in cancer of the esophagus and gastroesophageal junction A prospective study based on primary surgery with extensive lymphadenectomy Ann Surg 232 2000 743 752
73. M.B. Wallace, P.J. Nietert, C. Earle An analysis of multiple staging management strategies for carcinoma of the esophagus Computed tomography, endoscopic ultrasound, positron emission tomography, and thoracoscopy/ laparoscopy Ann Thorac Surg 74 2002 1026 1032
74. B.L. Brucher, W. Weber, M. Bauer Neoadjuvant therapy of esophageal squamous cell carcinoma Response evaluation by positron emission tomography Ann Surg 233 2001 300 309
75. R.J. Downey, T. Akhurst, D. Ilson Whole body 18FDG-PET and the response of esophageal cancer to induction therapy Results of a prospective trial J Clin Oncol 21 2003 428 432
76. W.A. Weber, K. Ott, K. Becker Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging J Clin Oncol 19 2001 3058 3065
77. R.J. Cerfolio, A.S. Bryant, B. Ohja The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy J Thorac Cardiovasc Surg 129 2005 1232 1241
78. I. Brink, M. Hentschel, T.A. Bley Effects of neoadjuvant radio-chemotherapy on 18F-FDG-PET in esophageal carcinoma Eur J Surg Oncol 30 2004 544 550
79. N. Arslan, T.R. Miller, F. Dehdashti Evaluation of response to neoadjuvant therapy by quantitative 2-deoxy-2-[18F]fluoro-D-glucose with positron emission tomography in patients with esophageal cancer Mol Imaging Biol 4 2002 301 310
80. R. Nakamura, T. Obara, S. Katsuragawa Failure in presumption of residual disease by quantification of FDG uptake in esophageal squamous cell carcinoma immediately after radiotherapy Radiat Med 20 2002 181 186
81. S.Y. Song, J.H. Kim, J.S. Ryu FDG-PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced, resectable esophageal cancer Int J Radiat Oncol Biol Phys 63 2005 1053 1059
82. M. Westerterp, H.L. van Westreenen, J.B. Reitsma Esophageal cancer CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy - systematic review Radiology 236 2005 841 851
83. P. Peller, J. Rauth, E. Norby PET scan evaluation of preoperative chemoradiotherapy in locally advanced esophageal cancer an accurate predictor of postsurgical outcome Radiol Soc N Am 2004 (abstr)
84. O. Vrieze, K. Haustermans, W. De Wever Is there a role for FGD-PET in radiotherapy planning in esophageal carcinoma? Radiother Oncol 73 2004 269 275
85. A. Konski, M. Doss, B. Milestone The integration of 18-fluoro-deoxy- glucose positron emission tomography and endoscopic ultrasound in the treatment-planning process for esophageal carcinoma Int J Radiat Oncol Biol Phys 61 2005 1123 1128
86. P. Flamen, A. Lerut, E. Van Cutsem The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancer J Thorac Cardiovasc Surg 120 2000 1085 1092
87. A. Stahl, K. Ott, W.A. Weber FDG PET imaging of locally advanced gastric carcinomas Correlation with endoscopic and histopathological findings Eur J Nucl Med Mol Imaging 30 2003 288 295
88. M. Yun, J.S. Lim, S.H. Noh Lymph node staging of gastric cancer using 18F-FDG PET A comparison study with CT J Nucl Med 46 2005 1582 1588
89. T. De Potter, P. Flamen, E. Van Cutsem Whole-body PET with FDG for the diagnosis of recurrent gastric cancer Eur J Nucl Med Mol Imaging 29 2002 525 529
90. K. Ott, U. Fink, K. Becker Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging Results of a prospective trial J Clin Oncol 21 2003 4604 4610
91. M.R. Hersh, J. Choi, C. Garrett Imaging gastrointestinal stromal tumors Cancer Control 12 2005 111 115
92. G.W. Goerres, R. Stupp, G. Barghouth The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours Long-term outcome of treatment with imatinib mesylate Eur J Nucl Med Mol Imaging 32 2005 153 162
93. I. Gayed, T. Vu, R. Iyer The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors J Nucl Med 45 2004 17 21
94. J.D. Lee, W.I. Yang, Y.N. Park Different glucose uptake and glycolytic mechanisms between hepatocellular carcinoma and intrahepatic mass-forming cholangiocarcinoma with increased (18)F-FDG uptake J Nucl Med 46 2005 1753 1759
95. W.Y. Lin, S.C. Tsai, G.U. Hung Value of delayed 18F-FDG-PET imaging in the detection of hepatocellular carcinoma Nucl Med Commun 26 2005 315 321
96. C.L. Ho, S.C. Yu, D.W. Yeung 11C-acetate PET imaging in hepatocellular carcinoma and other liver masses J Nucl Med 44 2003 213 221
97. M. Sugiyama, H. Sakahara, T. Torizuka 18F-FDG PET in the detection of extrahepatic metastases from hepatocellular carcinoma J Gastroenterol 39 2004 961 968
98. C.D. Anderson, M.H. Rice, C.W. Pinson Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma J Gastrointest Surg 8 2004 90 97
99. L.A. Orlando, S.L. Kulasingam, D.B. Matchar Meta-analysis the detection of pancreatic malignancy with positron emission tomography Aliment Pharmacol Ther 20 2004 1063 1070
100. S. Adams, R. Baum, T. Rink Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours Eur J Nucl Med 25 1998 79 83